Summary and Conclusions

  • David G. Nathan

Abstract

The management of aplastic anemia continues to challenge clinical investigators because the pathophysiology of the aplastic and hypoplastic syndromes is heterogeneous and poorly understood. The field can be further confused by investigators who assign pathophysiologic mechanisms as a result of therapeutic experiences. For example, the response of aplastic anemia to androgen therapy implies to some that the disease might be due to a deficiency of one or more growth factors or to a defect in the response of progenitor cells to normal or even elevated levels of growth factors. On the other hand, the response of aplastic anemia to bone marrow transplantation suggests that the disease could be due to destruction or dysfunction of stem cells or progenitor cells, while the response to prednisone of a single cell deficiency such as Diamond — Blackfan anemia suggests that the disorder may be due to failure of committed progenitor differentiation due perhaps to reduction of steroid-sensitive expression of a specific growth factor receptor gene. Finally, the response of aplastic anemia to antithymocyte globulin or cyclosporine or sometimes prednisone creates the impression that aplastic anemia is frequently an autoimmune disorder involving suppressor T cells. Indeed some cases of aplasia, particularly the single cell deficiencies, have been clearly associated with suppressing lymphocytes exhibiting a unique phenotype.1 Rarely serum antibodies reactive with committed progenitor cells have been detected.2 Therefore, there is little question that some cases of aplastic anemia are associated with dysregulation of the immune response, but whether the instigating agent is an autoantigen or, as seems more likely, a poorly regulated response to viral invasion of stem and/or progenitor cells is yet to be determined.

Keywords

Toxicity Hepatitis Europe Estrogen Leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lipton JM, Nadler LM, et al. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest 1983; 72:694.PubMedCrossRefGoogle Scholar
  2. 2.
    Abdou NI, Verdirame JD, et al. Heterogeneity of pathogenetic mechanisms in aplastic anemia. Efficacy of therapy based on in-vitro results. Ann Intern Med 1981; 95:43.Google Scholar
  3. 3.
    Abkowitz JL, Fialkow PJ, et al. Pancytopenia as a clonal disorder of a multipo-tent hematopoietic stem cell. J Clin Invest 1984; 73:258.PubMedCrossRefGoogle Scholar
  4. 4.
    Niemeyer CM, Sieff CA, et al. Expression of Human Interleukin-3 (multi-CSF) Is Restricted to Human Lymphocytes and T-Cell Tumor Lines. Blood 73(4):945, 1989.PubMedGoogle Scholar
  5. 5.
    Lipton JM, Linch D. The syndrome of T lymphocytosis: A model for the genetic restriction of hematopoietic suppression. In: Young NS, Levine AS, et al., eds. Aplastic Anemia: Stem Cell Biology and Advances in Treatment. New York, Liss, 1984: pp. 197–210.Google Scholar
  6. 6.
    Li FP, Alter BP, et al. The mortality of acquired aplastic anemia in children. Blood 1972; 40:153.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Inc. 1990

Authors and Affiliations

  • David G. Nathan

There are no affiliations available

Personalised recommendations